Perceptive Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Perceptive Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,360,858	Closed	-$10.9M	–	86
2025 Q1	$10.9M	Hold	5,360,858	–	–	0.38%	51
2024 Q4	$32.3M	Hold	5,360,858	–	–	0.89%	32
2024 Q3	$37.5M	Hold	5,360,858	–	–	0.79%	34
2024 Q2	$31.1M	Buy	5,360,858 +2,353,000	+78%	+$19M	0.75%	38
2024 Q1	$21.5M	Hold	3,007,858	–	–	0.38%	60
2023 Q4	$14.8M	Hold	3,007,858	–	–	0.33%	57
2023 Q3	$28.8M	Hold	3,007,858	–	–	0.96%	33
2023 Q2	$39M	Hold	3,007,858	–	–	1.13%	30
2023 Q1	$38.2M	Hold	3,007,858	–	–	1.13%	27
2022 Q4	$34.7M	Buy	+3,007,858	New	+$38.2M	0.97%	32

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Perceptive Advisors's ACRV Position: Q2 2025 in Review

Perceptive Advisors sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 5,360,858 shares — an estimated $10.9M sold.

Perceptive Advisors first reported a position in ACRV in Q4 2022 and held it in 10 quarters. The position peaked at $39M in Q2 2023. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

Perceptive Advisors reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
Perceptive Advisors sold 5,360,858 Acrivon Therapeutics shares in Q2 2025, an estimated $10.9M.
Perceptive Advisors first reported a position in Acrivon Therapeutics in Q4 2022 and held it in 10 quarters.
Perceptive Advisors's Acrivon Therapeutics position peaked at $39M in Q2 2023.
53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.